KRTAP10-3 Activators
Activators of KRTAP10-3 work primarily through pathways that modulate intracellular second messengers, particularly cyclic adenosine monophosphate (cAMP). When cAMP levels are elevated in the cell, it leads to the activation of a series of transcription factors, notably CREB (cAMP response element-binding protein). This has a direct impact on the expression levels of KRTAP10-3, as CREB binds to response elements in the DNA to enhance transcription. Certain activators increase cAMP by directly stimulating adenylate cyclase or by mimicking cAMP itself, which allows them to bypass the cell membrane and activate cAMP-dependent pathways from within. Others exert their effect by preventing the degradation of cAMP, thereby sustaining the activation of these pathways over a longer period.
The modulation of KRTAP10-3 is also influenced by the inhibition of phosphodiesterases, enzymes responsible for cAMP degradation. By inhibiting these enzymes, activators effectively raise the intracellular levels of cAMP, which indirectly leads to increased expression of KRTAP10-3 through prolonged CREB activation. Some activators even influence the activity of kinase enzymes, leading to a cascade of phosphorylation events that further ensure the activation of transcription factors involved in the expression of KRTAP10-3. Other activators impact G protein-coupled receptors, leading to increased intracellular cAMP and subsequent activation of the pathways that culminate in the upregulation of KRTAP10-3 expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A non-selective beta-adrenergic agonist that increases intracellular cAMP by activating adenylyl cyclase, which could promote KRTAP10-3 expression through cAMP response element-binding protein (CREB) activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterases, which prevents cAMP degradation, potentially leading to increased KRTAP10-3 expression through cAMP-mediated signaling pathways. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
A cAMP analog that is resistant to degradation by phosphodiesterases, potentially maintaining CREB activation and subsequent KRTAP10-3 expression. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
An activator of AMP-activated protein kinase (AMPK) that could enhance KRTAP10-3 expression through AMPK-mediated signaling pathways. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A membrane-permeable cAMP analog that directly activates cAMP-dependent pathways, potentially leading to increased KRTAP10-3 expression via CREB activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A selective inhibitor of phosphodiesterase-4 (PDE4), increasing cAMP levels, which may lead to CREB-mediated KRTAP10-3 expression. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
A tyrosine kinase inhibitor that can enhance cAMP levels by inhibiting cAMP degradation, this could support increased expression of KRTAP10-3 via cAMP-dependent pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
A selective inhibitor of phosphodiesterase-5 (PDE5), it elevates cAMP and cGMP levels, which could lead to increased KRTAP10-3 expression through cAMP/cGMP-dependent signaling pathways. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 activates EP2 and EP4 receptors, leading to increased intracellular cAMP, which may subsequently enhance KRTAP10-3 expression via CREB-dependent signaling. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
A PDE1 inhibitor that increases cAMP and cGMP levels, potentially leading to the activation of cAMP-dependent pathways and increased expression of KRTAP10-3. | ||||||